| |
Group |
Baseline |
Week 16 |
Group X time effects* |
| 1RM-sum of 8 lifts, kg |
UBR-Combined
CE+HE |
290 ± 98
313 ± 78 |
409 ± 149
350 ± 90 |
P < 0.001 |
| Whole body fat, % |
UBR-Combined
CE+HE |
30.3 ± 7.1
29.3 ± 7.4 |
29.6 ± 7.3
29.5 ± 7.4 |
P = 0.024 |
| Lean arm mass, kg |
UBR-Combined
CE+HE |
6.1 ± 1.8
6.1 ± 1.1 |
6.4 ± 1.9
6.1 ± 1.2 |
P = 0.003 |
| PImax, cm H2O |
UBR-Combined
CE+HE |
76.6 ± 26.2
75.6 ± 23.6 |
75.7 ± 25.8
71.5 ± 24.8 |
P = 0.166 |
| CRQ Dyspnea, scale score |
UBR-Combined
CE+HE |
4.1 ± 1.0
4.2 ± 1.1 |
4.6 ±1.2
4.2 ± 1.1 |
P = 0.053 |
| CRQ Fatigue, scale score |
UBR-Combined
CE+HE |
4.2 ± 1.1
4.4 ± 1.0 |
4.8 ± 1.2
4.9 ± 1.0 |
P = 0.145 |
| UB-FPT, laps |
UBR-Combined
CE+HE |
7.1 ± 1.6
6.8 ± 2.1 |
7.2 ±1.7
7.2 ± 2.0 |
P = 0.194 |
| FPI, total score |
UBR-Combined
CE+HE |
2.1 ± 0.4
2.1 ± 0.5 |
2.2 ± 0.5
2.2 ± 0.5 |
P = 0.316 |
| SE-Upper Body Resistance Training, total score |
UBR-Combined
CE+HE |
49 ± 21
49 ± 22 |
75 ±18
53 ± 23 |
P < 0.001 |
| SE-Upper Body Physical Activity, total score |
UBR-Combined
CE+HE |
58 ± 18
58 ± 25 |
66 ± 20
60 ± 23 |
P = 0.054 |
| BE-COPD, total score |
UBR-Combined
CE+HE |
75 ±18
77 ± 18 |
75 ± 22
70 ± 26 |
P = 0.137 |
Data are mean ± SD.
*Abbreviations: BE-COPD: Barriers Efficacy COPD Version; FPI: Functional Performance Inventory; PIMAX: Maximal Inspiratory Pressure; SE-Upper-Body Exercise:
Self-Efficacy for Upper-Body Exercise; SE-Upper Body Physical Activity: Self-Efficacy for Upper-Body Physical Activity; UB-FPT: Upper-Body Functional Performance Test
MANOVA between-subjects: Group F(1,62) = 0.739, P = 0.697; gender F(1,62) = 8.707, P < 0.001; FEV1 % predicted F(1,62) = 3.664, P = 0.001.
MANOVA within-subjects effects: time F(1,62) = 0.709, P = 0.724; interaction of time by group assignment F(1,62) = 3.720, P = 0.001; interaction of time by gender
F(1,62)=1.165, P = 0.335; interaction of time by disease severity (FEV1 % predicted) F(1,62) = 0.714, P = 0.719 (MANOVA P value is 2-tailed).
*Individual ANOVA P value is one-tailed. |
